New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09 mars 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
04 mars 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
29 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
22 janv. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
14 janv. 2024 04h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
15 déc. 2023 17h11 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
25 sept. 2023 09h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
18 avr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam...
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
09 mars 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
21 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...